Dr Sonja Gill (Heidorn)

AstraZeneca

NHS or other affiliations
Clinical Pharmacology and Safety Sciences

Position: Discovery Safety Specialist (DNA damage response and combinations)
Personal home page:

PubMed journal articles - click here

Research description

Safety assessment of oncology drugs (and combinations) with particular focus on the bone marrow.

Research Programme
Haematological Malignancies

Key publications

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma http://www.ncbi.nlm.nih.gov/pubmed/26505995 Systematic identification of genomic markers of drug sensitivity in cancer cells. http://www.ncbi.nlm.nih.gov/pubmed/22460902 Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. http://www.ncbi.nlm.nih.gov/pubmed/20141835